BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

BOT 1503 Study Analysis, page-3

  1. 691 Posts.
    lightbulb Created with Sketch. 160
    I think Matt's analysis is the first clean, understandable interpretation I have seen. It explains clearly that BTX1503 failed the Phase 2 and its back to the drawing board.

    thanks Matt for the concise analysis.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.